Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 21 June 1985:
Vol. 228. no. 4706, pp. 1436 - 1440
DOI: 10.1126/science.2409595
Prev | Table of Contents | Next

Articles

Science, Vol 228, Issue 4706, 1436-1440
Copyright © 1985 by American Association for the Advancement of Science

articles

Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria

F Zavala, JP Tam, MR Hollingdale, AH Cochrane, I Quakyi, RS Nussenzweig, and V Nussenzweig

Protective immunity against malaria can be obtained by vaccination with irradiated sporozoites. The protective antigens known as circumsporozoite (CS) proteins, are polypeptides that cover the surface membrane of the parasite. The CS proteins contain species-specific immunodominant epitopes formed by tandem repeated sequences of amino acids. Here it is shown that the dominant epitope of Plasmodium falciparum is contained in the synthetic dodecapeptide Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Pro or (NANP)3. Monoclonal antibodies and most or all polyclonal human antibodies to the sporozoites react with (NANP)3, and polyclonal antibodies raised against the synthetic peptide (NANP)3 react with the surface of the parasite and neutralize its infectivity. Since (NANP)3 repeats are present in CS proteins of P. falciparum from many parts of the world, this epitope is a logical target for vaccine development.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Two Decades of Commitment to Malaria Vaccine Development: GlaxoSmithKline Biologicals.
W. R. Ballou and C. P. Cahill (2007)
Am J Trop Med Hyg 77, 289-295
   Abstract »    Full Text »    PDF »
An Immunologically Cryptic Epitope of Plasmodium falciparum Circumsporozoite Protein Facilitates Liver Cell Recognition and Induces Protective Antibodies That Block Liver Cell Invasion.
D. Rathore, R. Nagarkatti, D. Jani, R. Chattopadhyay, P. de la Vega, S. Kumar, and T. F. McCutchan (2005)
J. Biol. Chem. 280, 20524-20529
   Abstract »    Full Text »    PDF »
Antigenic Diversity and Immune Evasion by Malaria Parasites.
M. U. Ferreira, M. da Silva Nunes, and G. Wunderlich (2004)
Clin. Vaccine Immunol. 11, 987-995
   Full Text »    PDF »
Unique T Cell Effector Functions Elicited by Plasmodium falciparum Epitopes in Malaria-Exposed Africans Tested by Three T Cell Assays.
K. L. Flanagan, E. A. M. Lee, M. B. Gravenor, W. H. H. Reece, B. C. Urban, T. Doherty, K. A. Bojang, M. Pinder, A. V. S. Hill, and M. Plebanski (2001)
J. Immunol. 167, 4729-4737
   Abstract »    Full Text »    PDF »
Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine.
Y. P. Shi, S. E. Hasnain, J. B. Sacci, B. P. Holloway, H. Fujioka, N. Kumar, R. Wohlhueter, S. L. Hoffman, W. E. Collins, and A. A. Lal (1999)
PNAS 96, 1615-1620
   Abstract »    Full Text »    PDF »
Application of Products Produced Through Biotechnology in Infectious Diseases.
S. E. Gorman and K. Plaisance (1991)
Journal of Pharmacy Practice 4, 103-116
   PDF »
Use of prior vaccinations for the development of new vaccines.
H. Etlinger, D Gillessen, H. Lahm, H Matile, H. Schonfeld, and A Trzeciak (1990)
Science 249, 423-425
   Abstract »    PDF »
Peptide immunogen mimicry of a protein-specific structural epitope on human choriogonadotropin.
J. Bidart, F Troalen, P Ghillani, N Rouas, A Razafindratsita, C Bohuon, and D Bellet (1990)
Science 248, 736-739
   Abstract »    PDF »
Conserved repetitive epitope recognized by CD4+ clones from a malaria-immunized volunteer.
E. Nardin, D. Herrington, J Davis, M Levine, D Stuber, B Takacs, P Caspers, P Barr, R Altszuler, P Clavijo, et al. (1989)
Science 246, 1603-1606
   Abstract »    PDF »
Limited immunological recognition of critical malaria vaccine candidate antigens.
M. Good, L. Miller, S Kumar, I. Quakyi, D Keister, J. Adams, B Moss, J. Berzofsky, and R Carter (1988)
Science 242, 574-577
   Abstract »    PDF »
Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides.
G. Lowell, W. Ballou, L. Smith, R. Wirtz, W. Zollinger, and W. Hockmeyer (1988)
Science 240, 800-802
   Abstract »    PDF »
Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications.
S. Hoffman, C. Oster, C. Plowe, G. Woollett, J. Beier, J. Chulay, R. Wirtz, M. Hollingdale, and M Mugambi (1987)
Science 237, 639-642
   Abstract »    PDF »
Use of Pyrimethamine-Sulfadoxine (Fansidar) in Prophylaxis Against Chloroquine-Resistant Plasmodium falciparum and Pneumocystis carinii.
R. D. PEARSON and E. L. HEWLETT (1987)
Ann Intern Med 106, 714-718
   Abstract »    PDF »
Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development.
J. Egan, J. Weber, W. Ballou, M. Hollingdale, W. Majarian, D. Gordon, W. Maloy, S. Hoffman, R. Wirtz, I Schneider, et al. (1987)
Science 236, 453-456
   Abstract »    PDF »
Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein.
M. Good, W. Maloy, M. Lunde, H Margalit, J. Cornette, G. Smith, B Moss, L. Miller, and J. Berzofsky (1987)
Science 235, 1059-1062
   Abstract »    PDF »
Research toward malaria vaccines.
L. Miller, R. Howard, R Carter, M. Good, V Nussenzweig, and R. Nussenzweig (1986)
Science 234, 1349-1356
   Abstract »    PDF »
Circumsporozoite protein of Plasmodium vivax: gene cloning and characterization of the immunodominant epitope.
D. Arnot, J. Barnwell, J. Tam, V Nussenzweig, R. Nussenzweig, and V Enea (1985)
Science 230, 815-818
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)